Pentoxifylline: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and its Therapeutic Efficacy

Drugs

Volumn 34, Issue 1, 1987, Pages 50-97

  Ward, Alan ^a   Clissold, Stephen P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; BUFLOMEDIL; DIHYDROERGOTOXINE; DIPYRIDAMOLE; ETOFYLLINE; FLUNARIZINE; NAFTIDROFURYL; PENTOXIFYLLINE; PIRACETAM; PLACEBO; PYRIDINOL; XANTHINOL NICOTINATE;

ADVERSE DRUG REACTION; BLOOD AND HEMOPOIETIC SYSTEM; BLOOD RHEOLOGY; BLOOD VISCOSITY; CARDIOTOXICITY; CEREBROVASCULAR DISEASE; DIGESTIVE SYSTEM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERANCE; EYE BLOOD FLOW; FLUSHING; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; HYPOBARISM; INTOXICATION; ISCHEMIC HEART DISEASE; MALE GENITAL SYSTEM; MICROCIRCULATION; NEUROTOXICITY; PERIPHERAL VASCULAR DISEASE; PERIPHERAL VASCULAR SYSTEM; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; SPERM; THROMBOCYTE AGGREGATION; VISUAL SYSTEM;

CARDIOVASCULAR DISEASES; HUMAN; PENTOXIFYLLINE; THEOBROMINE;

EID: 0023189396     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-198734010-00003     Document Type: Article

References (426)

1. Medical complications of computed tomography (part 1)
2. Medical complications of computed tomography (part 2)
3. Beneficial hemorheologic therapy of chronic peripheral arterial disorders with pentoxifylline: results of doubleblind study versus vasodilator nylidrin
4. Platelet adhesiveness in patients with cerebral vascular disease
5. The clinical effect of pentoxifylline (Trental) in the treatment of geriatric patients
6. Red cell flexibility and platelet aggregation in patients with chronic obstructive vascular disease (COAD) and study of therapeutic approaches
7. The role of fibrinolysis in the therapy of peripheral vascular disease
8. Studies on platelet aggregation and platelet interaction with tumor cells
9. Studies on platelet aggregation with pentoxifylline: effect in neoplastic disorders and other new indications
10. New clinical indications for Trental
11. The effect of pentoxifylline on regional vascular systems
12. Continuous infusion treatment with pentoxifylline in patients with severe peripheral vascular occlusive disease
13. Influence of pentoxifylline (Trental 400) on micro-circulation, post-stenotic blood pressure and walking capacity in patients with chronic occlusive arterial disease
14. Thrombozytenfunktion, plasmatische Blutgerinnung und Fibrinolyse bei chronisch arterieller Verschluss Krankheit
15. Coagulation phenomena and blood fluidity in peripheral occlusive arterial disease. Study with pentoxifylline
16. Zum Verhalten des Herzrhythmus bei digitalisierten Patienten mit zusätzlicher Pentoxifyllin-Medikation
17. The treatment of chronic arterial occlusion: a clinical study with a new formulation of pentoxifylline (Trental 400)
18. Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial disease
19. Hemodilution and pentoxifylline effects on muscle blood flow and blood fluidity in chronic arterial occlusive disease
20. Blood flow properties and walking performance in chronic arterial occlusive disease
21. Pentoxifylline (BL191) by oral administration in the treatment of asthenozoospermia
22. Trental forte en al tratamiento de pacientes con insuficiencia cerebrovascular
23. Clinical efficacy of pentoxifylline (BL191) and pyrithioxine hydrochloride in treatment of cerebrovascular disorders
24. Pentoxifylline: a new drug for the treatment of intermittent claudication
25. Is hyperviscosity a treatable component of diabetic microcirculatory disease?
26. Clinical trial with pentoxifylline in geriatric patients with cerebral circulatory insufficiency
27. Doppler ultrasonic blood pressure measurements in limbs with occlusive arterial disease and in normal lower extremities under treatment with pentoxifylline
28. A clinical pharmacological comparison of the two vasoactive compounds, pentoxifylline and xanthinol nicotinate
29. New prospects for the conservative management of peripheral arterial disease: clinical investigations with pentoxifylline (Trental 400)
30. Kinetics of intravenous and oral pentoxifylline in healthy subjects
31. Vaskuläre Erkrankungen des Augenhintergrundes
32. Therapeutische Erfahrungen bei Meniere und Hörsturz
33. Use of pentoxifylline in the treatment of acute cerebrovascular insufficiency
34. Influence of a single IV dose of pentoxifylline on central haemodynamics in patients with ischemic heart disease
35. Antineoplastic effect of the xanthine derivative, Trental
36. Effect of Trental on some renal function parameters in diabetes mellitus patients
37. Protection by pentoxifylline against ischemic deterioration of cerebral metabolism
38. The effect of pentoxifylline on the energy metabolism of ischemic gerbil brain
39. Protection by pentoxifylline against ischemic deterioration of cerebral metabolism
40. The effect of 3,7-dimethyl-1-(5-oxohexyl)-xanthin on the β-adrenergic receptors and on the activity of isoprenaline
41. Double-blind study of pentoxifylline against placebo in patients with intermittent claudication
42. Klinische Erfahrungen mit dem Vasotherapeutikum Trental in der Dermatologie
43. Red cell deformability and capillary blood flow
44. Clinical evaluation about pentoxifylline treatment in retinal branch vein occlusions
45. Evaluation of the action of pentoxifylline on the conjunctival microcirculation in diabetics
46. La pentossifillina nel trattamento delle arteriopatie obliteranti al secondo stadio
47. Determination of 1-(3′-carboxypropyl)-3,7-dimethylxanthine and 1-(4′-carboxybutyl)-3,7,-dimethylxanthine, two major metabolites of oxpentifylline, in urine by high-performance liquid chromatography
48. The effect of pentoxifylline on human erythrocyte adenosine triphosphate
49. Trials of 3,7-dimethyl-1-(5-oxohexyl) xanthine (BL191) in double-blind tests
50. Clinical experience of pentoxifylline in the microsurgery of intracranial aneurysms
51. Effects of methyl-xanthines upon the spermatozoa adenosinetriphosphate (ATP) concentration in normal semen
52. Effect of pentoxifylline and aminophylline on biogenic amine metabolism of the rat brain
53. Principles and techniques for assessing erythrocyte deformability
54. 14C) an Ratten, Hunde und Menschen
55. Can drug therapy alter the natural course of peripheral vascular disease
56. Clinical use of pentoxifylline — concerning blood viscosity and platelet function
57. Angioneuropathies, angiopathies and other circulatory disorders. Treatment of outpatients
58. The use of pentoxifylline in the treatment of intermittent claudication
59. Estudo eletroencefalografico e psicologico com BL-191 em pacientes geronto-psiquiatrico
60. Clinical pharmacology of pentoxifylline with special reference to its hemorheologic effect for the treatment of intermittent claudication
61. Effect of two phosphodiesterase inhibitors, cyclic adenosine 3’5’ monophosphate and a β-blocking agent on human sperm motility
62. Rheological and anticoagulant therapy of patients with chronic occlusive arterial disease
63. Effect of 3,7-dimethyl-1-(5-oxohexyl)-xantin (Trental, BL 191) on the blood viscosity factors in vitro
64. Studies of the clinical pharmacology and therapeutic efficacy of pentoxifylline in peripheral obstructive arterial disease
65. Change in red cell deformability and other haemorheological variables after myocardial infarction
66. Changes in red cell deformability following surgery
67. Therapeutische Ergebnisse beim akuten Myokardinfarct unter Anwendung hochdosierte Steroidgaben und fluidiläts beeinflussender Pharmaka
68. Vascular dementia and neuropsychological disorders of the ageing brain
69. Modification of psychometric, practical and intellectual parameters in patients with diffuse cerebrovascular insufficiency during prolonged treatment with pentoxifylline: a double-blind, placebo controlled trial
70. Experiences with Trental in stroke rehabilitation
71. Does oxpentifylline (Trental) have a place in the treatment of intermittent claudication?
72. What is viscosity?
73. Clinical importance of blood viscosity
74. Reduced red cell deformability
75. Clinical haemodynamic, rheological and biochemical findings in 126 patients with intermittent claudication
76. Prognostic significance of Theological and biochemical findings in patients with intermittent claudication
77. Conservative treatment of trophic skin ulcers with Trental
78. Editorial. Red cell deformability. Lancet 2: 1348–1349, 1978
79. Beeinflussung der Verformbarkeit der Erythrocyten durch Pentoxifyllin
80. The effect of pentoxifylline on the flow properties of hyperosmolar blood
81. The effect of pentoxifylline on the flow properties of human blood
82. New aspects of pathophysiology and therapy of chronic arterial diseases
83. Effects of orally administered pentoxifylline on muscular oxygen pressure in patients with intermittent claudication
84. Measurements of oxygen tension in muscle
85. The effect of pentoxifylline on the muscle tissue oxygen pressure of claudicants after pedoergometric exercise
86. The detection of changes in erythrocyte shape by a filtration method using 8 μm filters
87. The effect of pentoxifylline on the oxygen pressure of ischaemic muscle tissue in patients with chronic arterial occlusions
88. Blood viscosity and fibrinogen concentration following cerebral infarction
89. Central haemodynamics and coronary blood flow after administration of pentoxifylline to patients with coronary artery disease: a preoperative study
90. Hinweise zur Anwendung von Trental bei beginnender Symptomatik einer insuffizienten Hirndurchblutung
91. Zur Objektivierung der therapeutischen Wirksamkeit von Trental 400
92. Assessment of the therapeutic efficacy of pentoxifylline (Trental 400): a double-blind trial in geriatric patients with vascular disorders
93. Untersuchungen ueber die durchblutungsverbessemde Wirkung von BL 191 auf die Chorioidea des menschlichen Auges
94. Klinische Erfahrungen mit einem neuen Vasotherapeutikum bei Erkrankungen des Augenhintergrundes
95. In vitro effects of pentoxifylline on hemoglobin affinity for oxygen and electrolytic equilibrium of human blood
96. Studio comparato sull azione della pentoxifillina nelle occlusioni venose retiniche
97. Clinical and experimental investigations into the role of 3’, 5’ cyclic guanosine monophosphate (cGMP) in the mechanism of action of pentoxifylline
98. Durchblutungsstörungen des Netzhaut-Aderhaut-Bereichs und ihre Behandlungsmöglichkeiten mit Pentoxifylline
99. Neurologie diagnostic procedures
100. La nostra esperienza nel trattamento delle ulcere malleolari nella talessemia
101. Absorption, distribution, excretion and metabolism of 1-(5-oxohexyl)theobromine (BL 191) in rats
102. Studies on the hemorheological factors in ischemic heart disease and cerebrovascular disorders
103. The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia
104. Effets comparés sur la filtrabilité in vivo chez l’homme de deux formes galéniques de la pentoxifylline
105. Ergebnisse Indikationsstellung medikamentöser Therapie bei arteriellen und venösen Gefässverschlüssen der Retina durch Erythrosklerose
106. Cardioprotective actions of pentoxifylline in an animal model of acute myocardial ischaemia
107. Intermittent claudication: a double-blind crossover trial of pentoxifylline
108. Effect of pentoxifylline on cerebral edema in cats
109. Clinical investigation with a blood viscosity reducing agent in patients with peripheral vascular diseases
110. Etude multicentrique Torental 400 — arterite facteurs de risque vasculaire analyse intermediaire
111. The inhibition of cancer cell stickiness by the methyl-xanthine derivation pentoxifylline (BL 191)
112. Platelet-cancer cell interaction in metastasis formation: a possible therapeutic approach to metastasis prophylaxis
113. New aspects of the pathogenesis of atherosclerosis: possible approaches to prevention and treatment
114. Studies on platelet aggregation in vivo VII: effect of pentoxifylline on circulating tumour cells
115. Study of platelet aggregation in vivo III. Effect of pentoxifylline
116. Use of antiaggregating and haemostatic drugs in the treatment of diabetic retinopathy
117. Lack of effect of pentoxifylline on membrane lipid order and ion transports in human red cells
118. Successful treatment of Raynauds phenomenon with pentoxifylline
119. Comparative assessment of efficacy of various methods for treatment of diabetic retinopathies
120. The circulatory and clinical effects of pentoxifylline
121. Studies on platelet aggregation inhibitors in vivo. VIII. Effect of pentoxifylline on spontaneous tumor metastasis
122. Erythrozytenverformbarkeit Physiologie und Methodologie
123. Microrheological effects of the vasoactive compound 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine (Pentoxifylline, BL 191)
124. Blutviskosität und Diabetes mellitus
125. The effect of pentoxifylline on red cell flexibility in healthy subjects after administration of Trental 400
126. Effect of pentoxifylline on blood hyperviscosity and peripheral haemodynamics in patients with peripheral obliterating arterial disease
127. Studies on the erythrocyte osmotic fragility of patients suffering from vibration disease tested with the coil planet centrifuge
128. Cerebral blood flow in patients with cerebrovascular disorders — study with pentoxifylline
129. Effect of pentoxifylline on regional cerebral blood flow in patients with cerebral vascular disorders
130. Prolonged disturbances of cerebral blood flow in patients with transient ischemic attacks
131. Comparative randomized study of cerebral blood flow after long-term administration of pentoxifylline and co-dergocrine mesylate in patients with chronic cerebrovascular disease
132. Haemorheological treatment of acute cerebral ischaemia
133. Effect of pentoxifylline on regional CBF and CBV in dementia
134. Effects of pentoxifylline on cerebral ultrastructure of normal and ischemic gerbils
135. Therapeutische Möglichkeiten zur Vermeidung von stiellappennekrosen
136. The treatment of chronic cerebrovascular insufficiency. A double-blind study with pentoxifylline (Trental 400)
137. Clinical effectiveness of Trental (pentoxifylline) in the treatment of chronic arterial occlusive diseases
138. Measurements of local oxygen pressure in skeletal muscle of patients suffering from disturbances of arterial circulation
139. Studies on 3,7-Dimethyl-1-(5-oxo-hexyl)-xanthine (BL191). I. Cyclic 3,’5’-nucleotide phosphodiesterase (PDE) and the inhibitory effect of BL191 on PDE in rat brain and heart
140. Vasodilatantien und Blutviskosität
141. The effect of pentoxifylline on central and peripheral hemodynamics — an experimental clinical study
142. Blood glucose and serum insulin levels following acute and chronic pentoxifylline administration
143. Changes in blood viscosity due to pentoxifylline IRCS Medical
144. Therapeutic influence on flexibility of erythrocytes in sickle cell anemia
145. Effect of pentoxifylline on hypercoagulability in patients with polycythemia vera
146. Different types of therapy having haemorheological effects in patients with impairment of blood supply to the retina — randomised double blind study
147. Ophthalmologische Erfahrungen mit dem neuen Xanthinkörper BL 191
148. Infrarotthermographie zum Nachweis der Gefässwirksamkeit eines neuen Xanthinderivates
149. Der Einfluss von Pentoxifyllin auf das Spermiogramm. Eine Klinische Studie an Patienten mit herabgesetster Fertilität
150. Erfahrungen mit dem neuen Vasotherapeutikum Trental in der dermatologischen Fachpraxis
151. Zum Stellenwert der Mikrozirkulation in der Behandlung des Ulcus cruris
152. Treatment of retinal vein thrombosis
153. Trials of Trental in treatment of diabetic angiopathy
154. Preventive treatment of cerebral transient ischemia: comparative randomised trial of pentoxifylline vs conventional aggregants
155. Randomised trial of pentoxifylline versus acetylsalicylic acid + dipyridamole in preventing transient ischemic attacks
156. Medikamentöse Verbesserung der Fliesseigenschaften des Blutes
157. Analysis of 3,7-dimethyl-l-(5-oxo-hexyl)-xanthine. Part 1: The spectroscopy of 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine
158. Analysis of 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine. Part 2: Chromatography and quantitative estimation of BL 191
159. The pharmacokinetics of 3,7-dimethyl-l-(5-oxo-hexyl)-xanthine (BL191) in man
160. Structure of the excretion products of 3,7-dimethyl-l-(5-oxo-hexyl)-xanthine (BL 191) in man
161. Bioavailability and pharmacokinetics of pentoxifylline from Trental 400 in man
162. Clinical application of pentoxifylline to subfertile men, with regard to the statistical evaluation of the therapeutic effect of semen parameters
163. Untersuchung der zentralen Durchblutung mit Hilfe der Ophthalmodynamographie
164. Viskosität des Blutes unter Hörsturztherapie
165. Resultats d’une etude multicentrique randomisée en double aveugle: pentoxifylline contre placebo prolongee sur 6 mois dans les arteriopathies des membres inferieurs
166. Klinische Erfahrungen mit einem neuen Xanthinderivat (BL191) bei der Behandlung akuter Hörminderungen oder Ertaubungen
167. Pentoxifylline does not interfere with stable coumarin anticoagulant therapy: a clinical study
168. Influence of pentoxifylline (Trental) on platelet aggregation and serum lipids in patients with obstructive cerebrovascular disorders
169. Clinical use of pentoxifylline in haemorrhagic disorders of the retina
170. Oxpentifylline: effects on red cell deformability and oxygen availability from the blood in intermittent claudication
171. Pentoxifylline in strokes: a clinical study
172. The effect of oxpentifylline on fibrinolytic activity and plasma fibrinogen levels
173. Effect of pentoxifylline on red cell flexibility and cation transport in healthy subjects and patients with hereditary spherocytosis
174. Effect of pentoxifylline on red cell flexibility in arteriosclerotic patients with heart valve prosthesis
175. Polygraphische Registrierungen nach parenteraler Applikation von 3,7-dimethyl-l-(5-oxo-hexyl)-xanthin (BL191)
176. Statistical evaluation of polygraphic investigations of pentoxifylline
177. Déformabilité des hématies chez les diabétiques
178. Therapeutic experience with a Theologically active agent in an angiologic clinic
179. The clinical efficacy of Trental against various types of cerebrovascular diseases
180. Inhibitory effects of pentoxifylline on platelet aggregation
181. Experience with pentoxifylline in various vascular disorders of the fundus ocul
182. Amelioration of blood viscosity in sickle cell anemia by pentoxifylline: a case report
183. Medikamentose Therapie der Schwerhörigkeit
184. Zur Behandlung chronischer arterieller Durchblutungstörungen
185. Treatment of chronic arterial circulatory disorders: double-blind trial with pentoxifylline (Trental 400)
186. A pilot study: an open clinical trial of pentoxiphylline in patients with painful sickle cell crises
187. Therapie zerebraler Mikroangiopathien. Untersuchungen mit niedermolekular Hydroxyäthylstärke mit und ohne Pentoxifylline
188. Effects of pentoxifylline on 5-hydroxy-tryptamine in the mouse brain
189. Pentoxifylline and some physicochemical aspects of haemorheology in patients with ischaemic heart disease
190. The use of pentoxifylline in the treatment of ischaemic heart disease
191. Effect of pentoxifylline on cerebral blood flow and metabolism in dogs
192. The sickle cell diseases: clinical manifestations including the ‘sickle crisis’
193. Cerebral blood flow under hypobaric conditions: effects of pentoxifylline (Trental 400)
194. The effect of pentoxifylline on liver perfusion
195. Measurement of cerebral blood flow following intravenous administration of pentoxifylline (Trental)
196. The effects of pentoxifylline (Trental) on cerebral blood flow: a double-blind study
197. Retinale Durchblutung bei lakunären infarkten unter therapie mit Pentoxifyllin
198. Beneficial results of pentoxifylline (Trental) therapy in arteriosclerosis obliterans: possible mechanism of action
199. The effect of pentoxifylline on impaired red cell deformability following open-heart surgery
200. Preventive correction of hemostasis in polycythaemia vera patients
201. Effects of pentoxifylline on membrane protein phosphorylation in rat erythrocytes
202. The effect of pentoxifylline on circulatory disturbance of the retina and optic nerve: a report of ten years clinical experience
203. Influence of pentoxifylline (Trental) on platelet aggregation
204. The influence of pentoxifylline (Trental) on erythrocyte deformability — a new method for determining erythrocyte deformability
205. Pathologic erythrocytes in the capillary microcirculation
206. Effets de la pentoxifylline sur les modifications microcirculatoires au cours des arteriopathies (hypertension artérielle, diabète)
207. Klinische Bedeutung von Blutviskositätsveränderungen im Rahmen der zerebrovaskulären Insuffizienz
208. Konservative Therapie der cerebrovaskulären insuffisienz
209. Cerebrovascular disease: where are we now?
210. Effects of methylxanthine derivatives on red cell phosphorylation
211. Pharmacological influences of pentoxifylline on red cell filterability and 2–3, diphosphoglycerate
212. Pentoxifylline treatment of moderate to severe chronic occlusive arterial disease
213. A clinical study on pentoxifylline (Trental) in the treatment of cerebrovascular disease
214. The flow properties of whole blood under physiological and pathological conditions: microrheo-logical investigation
215. Ergebnisse der klinischen Prüfung des Vasotherapeutikums 3,7-Dimethyl-l-(5-Oxohexyl)-xanthin
216. Fünf Jahre klinisch-experimentelle und therapeutische Erfahrungen mit Pentoxifyllin
217. The flow properties of whole blood under physiological and pathological conditions: microrheological investigations
218. Effects of xanthine derivative (BL191) on insulin secretion in normal man
219. Effects of pentoxifylline on red blood cell deformability and blood viscosity under hyperosmolar conditions
220. Erythrocyte deformability in a red-cell ageing model
221. Interaction of pentifylline with mitochondria
222. The use of pentoxifylline in urological disorders
223. The effect of pentoxifylline on oxygen tension in renal tissue: experimental investigations
224. Réduction de la filtrabilité érythrocytaire et accidents vasculaires cérébraux
225. Effect of pentoxifylline on α- and β-adrenoceptor sites on cerebral cortex medial basal hypothalamus and pineal gland of the rat
226. Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study
227. The treatment of peripheral atherosclerosis with pentoxifylline
228. Ambulante Hörsturztherapie mit Dextran und Pentoxifylline
229. Effect of pentoxifylline (Trental) on cochlear blood flow as measured by hydrogen wash-out
230. Modificazioni emereologiche, emocoagulative e fotopletismografiche indotte dalla somministrazione di pentossifilline in soggetti con mallattic di Raynaud
231. Haemorheologische Therapie der peripheren arteriellen Versehlusskrankheit, Ergebnisse einer Feldstudie mit Trental forte
232. Some aspects of the potential clinical uses of pentoxifylline
233. Clinical and laboratory evaluation on the modification of erythrocyte flexibility induced by pentoxifylline
234. Primary prevention of atherosclerosis at high altitude
235. Red cell deformability: physiological, clinical and pharmacological aspects
236. La déformabilité érythrocitaire
237. Further studies on the effects of pentoxifylline on sperm count and sperm motility in patients with idiopathic oligo-asthenozoospermia
238. Pentoxifylline treatment of asthenozoospermia
239. Déformabilité des globules rouges et accidents vasculaires cérébraux: intérêt de la pentoxifylline
240. The effect of pentoxifylline on red cell deformability in cerebrovascular accidents
241. The use of pentoxifylline in diabetes mellitus
242. Pentoxifylline improves white cell rheology in claudicants
243. Enhanced blood circulation as a result of improved microcirculation
244. 2) by pentoxifylline from human vascular tissue
245. The effects of a new xanthine derivative, 3,7-dimethyl-1-(5-oxohexyl)-xanthin (pentoxifylline) on the general and cardiac haemodynamics of the intact animal
246. Behandlung arterieller und arterio-venöser Durchblutungsstörungen mit Trental
247. Intérêt de la pentoxifylline dans le traitement de la drépanocytose
248. Cerebrovascular diseases
249. Reduced erythrocyte deformability in diabetes
250. Clinical experience with pentoxifylline in the treatment of peripheral vestibular diseases — Results of a cooperative study
251. A study on blood viscosity in cerebrovascular disease
252. Proposta di assozione therapeutica emodilusione-pentossifillina nelle labirintopatie vascolari
253. The effect of pentoxifylline on cytotoxic form of ischemic brain edema in mongolian gerbil
254. Experiences with pentoxifylline in the treatment of peripheral vascular disease
255. The influence of pentoxifylline on skin-flap survival
256. Applicazione della filtrazione eritrocitaria nello studio della vasculopatia diabetica: efficacia terapeutica della pentossifillina
257. Lack of effect of pentoxifylline on chloride and glucose permeability in human red cells
258. Blood clotting, fibrinolytic and haemorheological parameters in ischaemic vascular disease: the effects of pentoxifylline in the treatment of acute cerebral vascular disease
259. Cerebrovascular insufficiency: its pathophysiology and therapeutic management
260. Pentoxifylline — a biomedical profile
261. Hemorheology and peripheral vascular diseases: a new therapeutic approach
262. On the therapy of disturbances of blood fluidity
263. Haemorheological role of platelet aggregation and hypercoagulability in microcirculation: therapeutical approach with pentoxifylline
264. Haemorheology and cerebrovascular disease: multi-functional approach with pentoxifylline
265. Zum Wirkungsmechanismus von Pentoxifyllin
266. Haemorheology in surgery — a review
267. The treatment of chronic arterial blood circulation interference
268. The use of pentoxifylline in the treatment of torpid ankle ulcers in thalassaemia major
269. Ex vivo human platelet aggregation induced by decompression during reduced barometric pressure, hydrostatic, and hydrodynamic (Bernoulli) effect
270. Experience with pentoxifylline in the treatment of peripheral arterial disease
271. Adenosine triphosphate and maintenance of shape of human red cells
272. Pathophysiology of cerebral blood flow in brain ischemia
273. Functional vascular disease: treatment with pentoxifylline
274. Disorders of hemocoagulation and fibrinolysis in patients with chronic renal failure during treatment with haemodialysis and approaches to its correction
275. Effect of pentoxifylline on platelet aggregation
276. Platelet survival in patients with artificial heart valves and the effect of anti-platelet agents
277. Interêt d’un medicament augmentant la déformabilité des globules rouges (pentoxifylline-Torental) dans le traitement de la drepanocytes
278. Effects of pentoxifylline on cell shape, ATP content and deformability in rabbit erythrocytes under hyperosmolar conditions
279. Lungenfunktionsuntersuchungen zur bronchospasmolytischen Wirkung von 3,7-Dimethyl-l-(5-Oxo-hexyl)-Xanthin
280. Effects of pentoxifylline on central haemodynamics in patients with congestive heart failure
281. Influence of intravenously administered pentoxifylline on endogenous secretion of catecholamines
282. Effect of pentoxifylline on microvascular blood flow velocity
283. Beeinflussung der Lappendurchblutung und Nekroserate nach Verschiebeschwenkplastik durch Pentoxifyllin und Dextran 40
284. Azione della pentossifillina sulla velocità del angue aortico nella stenosi valvolare dell’aorta
285. 2 Messung in der Dermatologie
286. The clinical importance of haemorheological alteration in cerebrovascular disease
287. Möglichkeiten und Grenzen der Behandlung zerebrovaskulärer Risikofaktoren
288. Haemorheological effects of pentoxifylline in disturbed blood flow behaviour in patients with cerebrovascular disease
289. The rationale of rheological pharmacological therapy
290. Changes of flow properties of the blood in cerebrovascular disease and their medical treatment with pentoxifylline
291. High blood viscosity syndrome in cerebral infarction
292. Changes in the rheologic properties of blood after a high altitude expedition
293. Esperienze terapeutiche con pentossifillina nella ipoacusia neurosensoriale e nella malattia di ménière
294. The role of haemorheological factors in the ageing brain: long-term therapy with pentoxifylline (Trental 400) in elderly patients with initial mental deterioration
295. Haemorheological pattern in initial mental deterioration: results of a longterm study using piracetam and pentoxifylline
296. The action of oxpentifylline on the central fusion frequency in subjects with chronic ischaemic maculopathy
297. Effect of pentoxifylline on cerebral blood flow in patients with chronic cerebrovascular disease
298. Torental et accidents ischémiques du système nerveux central
299. Pentoxifyllin-Medikation im Rahmen der Ulcus cruris-Behandlung. Ergebnisse einer Feldstudie mit Trental 400
300. Haemorheological aspects of the pathophysiology and clinical features of peripheral occlusive arterial disease
301. Haemorheological improvement by pentoxifylline in patients with peripheral arterial occlusive disease
302. Effects of flunarizine and pentoxifylline on walking distance and blood rheology in claudication
303. Pentoxifylline in the neurological clinic
304. L’uso della pentossifillina nei diabetici con claudicatio infernilbeus
305. P-31 nuclear magnetic resonance study of pentoxifylline effect on experimental cerebral ischemia
306. Comparative evaluation of buflomedil and pentoxifylline in patients with peripheral arterial occlusive disease
307. L’insufficienza cerebrovascolare cronica senile. Effetti del suloctidil e della pentossifillina sulla deformabilita eritrocitaria
308. Possibilities of conservative therapy of chronic renal insufficiency
309. Pentoxifylline in the treatment of chronic hypoacousias: a clinical and audiometric study
310. Pentoxifylline in the combination therapy of pyelonephritis
311. Pentoxifylline treatment in patients with occlusive peripheral arterial disease. Circulatory changes and effects on prostaglandin synthesis
312. 2 in healthy volunteers
313. Zur Pharmakologie des neuen peripheren Gefassdilatators 3,7-dimethyl-l-(5-oxohexyl)-xanthin
314. The effect of pentoxifylline on ATPase activity of human erythrocyte membranes
315. The influence of pentifylline and theophylline on reaction kinetics on rat brain ATPase stimulable by catecholamines
316. Pharmacologic approaches to intermittent claudication and vasospasm
317. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients
318. Use of a new vasoactive drug in geriatric patients with cerebral circulatory insufficiency
319. Farmacologia clinica delle sostanze vasoattive: studi sulla pentossifilline
320. Clinical pharmacology of vasoactive drugs: studies on pentoxifylline
321. The effect of pentoxifylline on haemodynamic indices and tolerance to physical load in the treatment of patients with IHD (Russ)
322. Double-blind clinical trial with BL-191 3,7-Dimethyl (l-(5’-oxohexil)-3,7-dimetilxantine) in the treatment of patients bearing a peripheric vestibular syndrome of vascular etiology
323. Shunt thrombosis prevention in haemodialysis patients — double blind controlled study pentoxifylline versus placebo
324. A clinical-pharmacologic study of the effect of pentoxifylline on hormone secretion in man
325. The comparative effects of three vasoactive compounds (oxpentifylline, prazosin and indorman) on the blood rheology of beagle dogs
326. A simple method for measuring erythrocyte deformability
327. Impaired red cell deformability in peripheral vascular disease
328. Nuovi criteri terapeutici in corso du vasculopatie cerebrali croniche diffuse
329. Studies on osteoporoses. XI. Effects of a methyl-xanthine derivative
330. Study of antiosteoporotic agents in tissue culture
331. Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration
332. Ruolo e possibile controllo dei fattori di rischio nell vasculopatie artersclerotiche per la valutazione dei risultati del trattamento chirurgico: studio preliminare sull’ impiego dell pentossifillina
333. The effect of pentoxifylline on haemodynamic and ergometric variables in patients with arterial occlusive disease (Stage II)
334. Pharmacology and clinical trials of pentoxifylline
335. Red cell deformability in patients with cerebral vasospasm
336. Protective effect of pentoxifylline on experimental thrombosis induced by stenosis of femoral artery in rabbits
337. Deformability of erythrocyte in cerebrovascular disorders
338. The usage of disaggregants for the treatment of diabetic retinopathy
339. The use of pentoxifylline in a combined regimen for the prevention of re-thrombosis in major blood vessels
340. Pentoxifylline (Trental) therapy for the vasculitis of atrophic blanche
341. Effects of pentoxifylline on the endotoxin induced shock reaction
342. Untersuchungen zur Pharmacokinetik von Pentoxifyllin bei chronischer Niereninsuffizienz
343. Erfahrungen mit Trental bei peripheren Druchblutungsstörungen und zerebrovaskulärer Insuffizienz
344. Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi
345. Therapie der idiopathischen Aestheno- und Oligozoospermie mit Pentoxifyllin
346. Pentoxifyllin und seine klinische Anwendung bei Durchblutungsstoerungen
347. Clinical use of pentoxifylline
348. Filterability of subpopulations of leukocytes: effect of pentoxifylline
349. Red-cell aggregation and red-cell deformability in diabetes
350. A simple method for measuring red cell deformability in models of the microcirculation
351. Influence of deformability of human red cells upon blood viscosity
352. Behandlung lakunärer Infarkte mit Pentoxifyllin
353. The rheological efficiency of parenteral pentoxifylline (Trental) in patients with ischemic brain lesions
354. Die Konzentration von Pentoxifyllin bei oraler Gabe in Seminalplasma
355. Effects of naftidrofuryl, pentoxifylline and bencyclane on the renal blood flow and renal excretion of conscious dogs
356. The release of prostacyclin by pentoxifylline from human and animal vascular tissue and its implications for vascular and antiplatelet activities
357. Antithrombotic potential of pentoxifylline — a hemorheologically active drug
358. Double-blind trial of pentoxifylline in diabetics with peripheral vascular disorders
359. The effect of pentoxifylline on erythrocyte deformability and on phosphatide fatty acid distribution in the erythrocyte membrane
360. 2 of human brain cortex-method, basic results and effects of pentoxifylline
361. Blutviskosität und Innenohrschwerhörigkeit
362. Effect of pentoxifylline on red cell aggregation (RCA)
363. Micro mechanical methods to determine haemorheological parameters
364. Effect of pentoxifylline on sickle cell thalassaemia: haemorheological and clinical results
365. Effect of pentoxifylline on single red cell deformability
366. Filterability investigations with red blood cell (RBC) suspensions: effects of different blood components and pentoxifylline on RBC flow rate
367. Antithrombotic effects on pentoxifylline on laser-induced thrombi in rat mesenteric arteries
368. Diabetes mellitus und Mikrozirkulation
369. Clinical experience with pentoxifylline in occlusive cerebrovascular disorders
370. Pentoxifylline enhances formation of protacyclin from rat vascular and renal tissue
371. Erythrocyte flexibility and metabolism
372. The use of pentoxifylline in insulin dependent diabetics, with late complications
373. Pharmacokinetics of orally administered pentoxifylline in humans
374. Changes in blood viscosity induced by pentoxifylline
375. Diabetic retinal vascular complications and erythrocyte filtrability: results of a 2 year follow-up study with pentoxifylline
376. Pentoxifylline, albumin excretion rate and proteinuria in type I and II diabetic patients with microproteinuria. Results of a short term randomised study
377. Aremerkungen zur Therapie der idiopathischen Facialisparese
378. The effect of pentoxifylline on filterability of normal red blood cells and their adhesiveness to cultured endothelial cells
379. Treatment of microcirculation disorders with Trental and Complanum in patients with diabetes mellitus
380. Adherence of elderly patients to treatment with pentoxifylline
381. Kardiale Wirkung von Pentoxifyllin bei Patienten mit Koronarer Herzerkrankung in Ruhe und während Belastung
382. Pentoxifylline does not protect mice against hypoxia
383. Pentoxifylline does not change cerebral blood flow or metabolism in the dog
384. Pentoxifylline in regional cerebral ischemia in cats
385. The biochemical mechanism of action of pentoxifylline
386. The effect of pentoxifylline on the 3’5’ cyclic AMP-system in bovine platelets
387. Influence of pentifylline on brain metabolism of normal and anoxic rats
388. Effect of pentoxifylline on brain adenine nucleotide levels in anoxic rats
389. On the influence of pentoxifylline on the permeability of rat erythrocytes for methyl-0-glucose
390. Clinical investigation of the effects of pentoxifylline in patients with severe peripheral occlusive vascular disease
391. Bell’s palsy — a new concept of treatment
392. Pathomechanisms in cell metabolism: a key to treatment of Bell’s palsy
393. Zur Rheologie des Blutes bei arteriellen Verschlusskrankheiten
394. Rheological changes in the blood of patients with chronic arterial occlusive disease after the administration of vasoactive drugs
395. Modificazioni di alcuni parametri emoreologici in dolte dal trattamento con pentoxifillina in pazienti affelti da progresso infarto del myocard
396. Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs
397. Effect of dipyridamole plus pentoxifylline in patients with diffuse cerebrovascular insufficiency
398. Valutazione clinica ed emodinamica dell’azione della pentossiflllina nei pazienti con arteriopatia ostruttiva degli arti inferiori
399. The effect of pentoxifylline on the flow properties of blood in experimental atherosclerosis in rabbits
400. Effects of pentoxifylline on energy metabolism in washed human erythrocytes